Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Biogen, Inc.
New markets, a patent cliff, an M&A rebound and clinical trial catalysts. How will it all play out for the biopharma sector in 2024?
Less than two years after its $101m series A round, Seismic’s machine-learning powered IMPACT platform for biologics drug discovery yielded two clinical trial-ready assets worthy of a $121m series B.
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
Eisai’s initiatives in Thailand mark the company's first attempts to collaborate directly with government organizations to address dementia-related issues. The major Japanese firm teamed up with the country’s largest private insurance firm in 2022 to extend coverage to Alzheimer's and is planning to file locally for Leqembi’s approval by March 2024.
- Specialty Pharmaceuticals
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- Biogen Idec
- Convergence Pharmaceuticals Ltd
- Nightstar Therapeutics plc
- Stromedix, Inc.
- Syntonix Pharmaceuticals
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.